Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 24, 2017
Pharmacy Choice - Pharmaceutical News - UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA - September 24, 2017

Pharmacy News Article

 9/11/17 - UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration (see also Oncology - Acute Lymphoblastic Leukemia).

Chimeric antigen receptor T-cell, or CAR T-cell, therapy, targets two common forms of cancer and has been used in clinical trials at UChicago Medicine to treat both ALL and diffuse large B-cell lymphoma (DLBCL) in adults.

"CAR T-cell therapy has revolutionized the treatment of acute lymphoblastic leukemia," according to cancer specialist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children's Hospital. "I came to the United States 30 years ago with the intent to work on therapies such as this. We need focused treatments like this that can eradicate particular types of cancer."

One of the cancers, B-cell acute lymphoblastic leukemia, is the most common childhood cancer. ALL is a rapidly progressive leukemia that primarily affects children and young adults, from age 3 to 25. Nearly 3,100 patients under 21 years old in the U.S. will be diagnosed with ALL this year.

Used to supplement forms of cancer treatment like chemotherapy, radiation and stem cell transplants, CAR T-cell therapy works by using modified versions of a patient's own blood cells to target and destroy cancer cells.

UChicago Medicine is working with Novartis, the maker of Kymriah, to be part of a national network offering the treatment to pediatric patients in Chicago. The effort for pediatric patients is being spearheaded by Cunningham. The FDA approved the use of Kymriah in people up to age 25. Novartis announced it plans to use clinical outcomes to help determine the cost of treatment.

Ninety percent of pediatric patients with ALL enrolled in early CAR T-cell clinical trials throughout the country went into lasting remission. DLBCL patients often relapse after standard treatments, but those treated with CAR T-cell therapy have doubled the long-term survival rate. Now, about 50 percent of those patients appear to have lasting complete remissions.

The FDA approved Kymriah for use in pediatric ALL patients and is expected to approve a CAR T-cell therapy for treatment of DLBCL and ALL in adults being developed by Kite Pharma Inc.

Sam Tinaglia, 18, of Park Ridge was one of the first 100 children in the country to participate in clinical trials of CAR T-cell therapy for acute lymphoblastic leukemia. Diagnosed in 2003 at age 5, Tinaglia relapsed for the first time five years after initial treatment. Over the next seven years, doctors tried more rounds of chemotherapy and a bone marrow transplant. With each recurrence his chances of survival lessened.

"We thought we had reached the end, " said Sam's mother, Suzie. "But then Dr. Cunningham told us about the CAR T-cell clinical trial that was giving hope to kids, like Sam, who had no other options."

In 2015, during his junior year of high school, Sam underwent CAR T-cell therapy at Children's Hospital of Philadelphia. "Six weeks later, they sent me home and that was pretty much it," said Sam, who just started his freshman year of college. "I'm obviously very happy, because my cancer, hopefully is gone forever."

Keywords for this news article include: Biotechnology, Biomedical Engineering, Biomedicine, Pharmaceutical Companies, Genetics, Hospital, Hematology, Pediatrics, Novartis AG, Cell Therapy, Bioengineering, Clinical Research, Biological Therapy, Cancer Gene Therapy, Drugs and Therapies, Leukemia Gene Therapy, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 25: Management of Major Depressive Disorders
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Sep 29: Legal & Practical Issues in Compounding Pharmacy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415